France Pharmaceuticals & Healthcare Report

Published 05 June 2015

  • 133 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
France Pharmaceuticals & Healthcare Report

BMI View: Improvements in leading high-frequency indicators for the French economy, including consumer confidence, will continue to pose upside risks to our pharmaceuticals and healthcare growth forecasts over a multi-quarter horizon. However, while domestic and eurozone improved growth readings will put France back on investors' radars, regulatory encumbrances affecting labour market costs will continue to weigh on the country's full potential, including the pharmaceutical sector. Meanwhile, an increase in the uptake of generic medicines and other cost-control efforts by the government will be combined with measures to improve and extend access to healthcare, sustaining demand and overall sector growth over the long term.

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.06bn (USD44.29bn) in 2014 to EUR32.43bn (USD35.67bn) in 2015; -1.9% in local currency terms and -19.5% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: EUR246.20bn (USD329.91bn) in 2014 to EUR253.19bn (USD278.50bn) in 2015; +2.8% in local currency terms and -15.6% in US dollar terms. Forecast revised downwards from last quarter.

Risk/Reward Index

In Q315 France shifted upwards one ranking position in our Risk/Reward Index (RRI) matrix, standing as the third most attractive market to pharmaceutical investors out of 15 markets in Western Europe. However, lower scores in other markets in the region explain the ranking variation, while France maintains an overall score of 71.7 out of 100. France's score is boosted by the large multi-billion dollar drug market (market expenditure score of 16.0 out of 20), and large pensionable population (pensionable population score of 8.0 out of 8), but dragged down by poor market expansion (sector value growth score of 0.0 out of 12).

Key Trends And Developments

April 2015

  • The recent health reforms in France have drawn opposition from doctors, reports PMlive. The long list of reforms proposed by the health minister Marisol...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2011-2019)
21
Prescription Drug Market Forecast
22
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2011-2019)
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2011-2019)
25
Generic Drug Market Forecast
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (France 2011-2019)
29
OTC Medicine Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2011-2019)
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecasts (France 2013-2019)
35
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2013-2019)
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
37
Economic Analysis
37
Table: GDP By Expenditure (France 2012-2019)
43
Industry Risk Reward Ratings
44
Western Europe Risk/Reward Index
44
France Risk/Reward Index
48
Rewards
48
Risks
49
Market Overview
50
Industry Trends And Developments
51
Epidemiology
51
Health System Structure And Financing
52
Prescription Drugs
54
Healthcare Financing: Cost Containment Measures
55
Healthcare Provision
57
Public Hospitals
58
Table: Hospital Activity, 2005-2009
59
Table: Hospital Activity in Short-Stay Units, 2009
60
Table: Diagnostic & Therapeutic Procedures Performed In Public & Private Hospitals, 2009
61
Table: Projected Regional Ranking Of Physicians, 2017
62
Table: Health Status
63
Table: Healthcare Funding
63
Table: Healthcare Resources (France 2009-2014)
64
Table: Healthcare Personnel (France 2009-2014)
64
Table: Healthcare Activity (France 2009-2014)
65
Research & Development
66
Biotechnology
68
Clinical Trials
71
Regulatory Development
73
Intellectual Property Issues
75
Pricing & Reimbursement
76
Table: France Reimbursement Categories
76
Biosimilars
79
OTC Medicines
84
Competitive Landscape
86
Research-Based Industry
86
Generic Drugmakers
90
Pharmaceutical Distribution
90
Pharmaceutical Retail Sector
91
Company Profile
93
Sanofi
93
Servier
101
Ipsen
106
Pfizer
110
GlaxoSmithKline
113
Novartis
116
Merck & Co
119
Demographic Forecast
121
Table: Population Headline Indicators (France 1990-2025)
122
Table: Key Population Ratios (France 1990-2025)
122
Table: Urban/Rural Population & Life Expectancy (France 1990-2025)
123
Table: Population By Age Group (France 1990-2025)
123
Table: Population By Age Group % (France 1990-2025)
124
Glossary
126
Methodology
128
Pharmaceutical Expenditure Forecast Model
128
Healthcare Expenditure Forecast Model
128
Notes On Methodology
129
Risk/Reward Index Methodology
130
Index Overview
131
Table: Pharmaceutical Risk/Reward Index Indicators
131
Indicator Weightings
132

The France Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for France, to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%